Eikon Therapeutics Files for IPO Led By Merck Veterans

Eikon Therapeutics Inc. filed for an initial public offering to help fund its advanced pipeline of cancer drugs.

The company plans for its shares to trade on the Nasdaq Global Market under the symbol EIKN, according to a filing Friday with the US Securities and Exchange Commission. JPMorgan Chase & Co., Morgan Stanley, Bank of America Corp and Cantor Fitzgerald are working on the offering.